SI9520091B - Soli anti-migrenskega derivata indola - Google Patents

Soli anti-migrenskega derivata indola Download PDF

Info

Publication number
SI9520091B
SI9520091B SI9520091A SI9520091A SI9520091B SI 9520091 B SI9520091 B SI 9520091B SI 9520091 A SI9520091 A SI 9520091A SI 9520091 A SI9520091 A SI 9520091A SI 9520091 B SI9520091 B SI 9520091B
Authority
SI
Slovenia
Prior art keywords
compound
formula
polymorphic form
solvent
suitable solvent
Prior art date
Application number
SI9520091A
Other languages
English (en)
Slovenian (sl)
Other versions
SI9520091A (sl
Inventor
Valerie Denise Harding
Ross James Macrae
Ronald James Ogilvie
Original Assignee
Pfizer Research And Development Company, N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10760474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9520091(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Research And Development Company, N.V./S.A. filed Critical Pfizer Research And Development Company, N.V./S.A.
Publication of SI9520091A publication Critical patent/SI9520091A/sl
Publication of SI9520091B publication Critical patent/SI9520091B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)
SI9520091A 1994-08-27 1995-05-17 Soli anti-migrenskega derivata indola SI9520091B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417310A GB9417310D0 (en) 1994-08-27 1994-08-27 Therapeutic agents
PCT/EP1995/001914 WO1996006842A1 (en) 1994-08-27 1995-05-17 Salts of an anti-migraine indole derivative

Publications (2)

Publication Number Publication Date
SI9520091A SI9520091A (sl) 1998-02-28
SI9520091B true SI9520091B (sl) 2004-10-31

Family

ID=10760474

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9520091A SI9520091B (sl) 1994-08-27 1995-05-17 Soli anti-migrenskega derivata indola

Country Status (45)

Country Link
US (2) US6110940A (fi)
EP (1) EP0776323B1 (fi)
JP (1) JP2904588B2 (fi)
KR (1) KR100228952B1 (fi)
CN (1) CN1066727C (fi)
AP (1) AP576A (fi)
AT (1) ATE163182T1 (fi)
AU (1) AU691005B2 (fi)
BG (1) BG61840B1 (fi)
BR (1) BRPI9503812B1 (fi)
CA (1) CA2198599C (fi)
CO (1) CO4410334A1 (fi)
CZ (1) CZ287693B6 (fi)
DE (1) DE69501620T2 (fi)
DK (1) DK0776323T3 (fi)
DZ (1) DZ1923A1 (fi)
EG (1) EG23822A (fi)
ES (1) ES2112650T3 (fi)
FI (1) FI113768B (fi)
GB (1) GB9417310D0 (fi)
GR (1) GR3026475T3 (fi)
HR (1) HRP950460B1 (fi)
HU (1) HU227822B1 (fi)
IL (1) IL115013A (fi)
IS (1) IS1850B (fi)
LV (1) LV11800B (fi)
MA (1) MA23650A1 (fi)
MX (1) MX9701538A (fi)
MY (1) MY113733A (fi)
NO (1) NO311297B1 (fi)
NZ (1) NZ288210A (fi)
OA (1) OA10600A (fi)
PE (1) PE41596A1 (fi)
PL (1) PL180867B1 (fi)
RO (1) RO116400B1 (fi)
RU (1) RU2159241C2 (fi)
SA (1) SA95160156B1 (fi)
SI (1) SI9520091B (fi)
SK (1) SK282922B6 (fi)
TN (1) TNSN95092A1 (fi)
TR (1) TR199501061A2 (fi)
UA (1) UA45980C2 (fi)
WO (1) WO1996006842A1 (fi)
YU (1) YU49287B (fi)
ZA (1) ZA957142B (fi)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
GB9714081D0 (en) * 1997-07-03 1997-09-10 Pfizer Ltd Pharmaceutical compositions
NZ501419A (en) * 1997-07-03 2000-09-29 Pfizer Pharmaceutical compositions containing eletriptan hemisulphate and caffeine for treating migraines, depression and eating disorders
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
GB0008563D0 (en) 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US20030166704A1 (en) * 2000-12-20 2003-09-04 Pfizer Inc. New process
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
JP2006522790A (ja) 2003-04-11 2006-10-05 ファイザー・インク エレトリプタンと重炭酸ナトリウムを含む医薬組み合わせ物
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
EP2502621A1 (en) * 2005-06-27 2012-09-26 Valeant International (Barbados) SRL Crystalline forms of bupropion HBr
CN101687788A (zh) * 2006-10-19 2010-03-31 奥斯拜客斯制药有限公司 取代的吲哚
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP1956018A1 (de) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung eines Benzimidazolderivats
EP2046777A2 (en) 2007-05-01 2009-04-15 Plus Chemicals B.V. Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
EP2038273A1 (en) * 2007-05-29 2009-03-25 Plus Chemicals B.V. A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole
EP2225224A2 (en) * 2007-12-17 2010-09-08 Actavis Group PTC EHF Novel hemioxalate salt of eletriptan
WO2009142771A2 (en) * 2008-05-22 2009-11-26 Plus Chemicals, S.A. Salts of (r)-5-(2-phenylsulphonylethenyl)-3-(n- methylpyrrolidin-2-ylmethyl)-1h-indole, 5-bromo-3-[(r)-1- methyl-pyrrolidin-2- ylmethyl]-1h-indole and of eletriptan
US8349900B2 (en) * 2008-08-07 2013-01-08 Valeant International Bermuda Bupropion hydrobromide polymorphs
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
US8754239B2 (en) 2010-01-19 2014-06-17 Sms Pharmaceuticals Limited Process for preparing eletriptan hydrobromide having α-form
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
JP2019502761A (ja) 2016-01-21 2019-01-31 ラボラトリオス レヴィ エセエレ （（ｒ）−３−［（−１−メチルピロリジン−２−イル）メチル］−５−（２−フェニルスルホニルエチル）−１ｈ−インドールを作製する方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
HUT64326A (en) * 1990-10-15 1993-12-28 Pfizer Process for production indole derivatives and pharmaceutical preparations containing these compounds
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
DE69230803T2 (de) * 1991-11-25 2000-12-07 Pfizer 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (fi) * 1992-03-05 1996-10-11 Pfizer
AU670579B2 (en) * 1992-04-07 1996-07-25 Pfizer Inc. Indole derivatives as 5-HT1 agonists
DK0635015T3 (da) * 1992-04-10 1997-03-17 Pfizer Acylaminoindolderivater som 5-Htl agonister
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
BR9406481A (pt) * 1993-04-22 1996-01-09 Pfizer Res & Dev Derivados de indol como agonistas do tipo 5-HT1 para utilização na enxaqueca
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
DE69413240T2 (de) * 1993-08-31 1999-02-04 Pfizer 5-arylindolderivate

Also Published As

Publication number Publication date
CA2198599C (en) 2000-06-06
FI113768B (fi) 2004-06-15
SA95160156B1 (ar) 2005-05-30
FI970800A0 (fi) 1997-02-26
NZ288210A (en) 1998-01-26
RO116400B1 (ro) 2001-01-30
MA23650A1 (fr) 1996-04-01
KR100228952B1 (ko) 1999-11-01
AU2735295A (en) 1996-03-22
PL180867B1 (pl) 2001-04-30
EP0776323A1 (en) 1997-06-04
NO311297B1 (no) 2001-11-12
SK282922B6 (sk) 2003-01-09
BRPI9503812B1 (pt) 2017-04-18
BR9503812A (pt) 1996-04-16
MY113733A (en) 2002-05-31
IS4401A (is) 1996-12-19
EG23822A (en) 2007-09-19
SI9520091A (sl) 1998-02-28
FI970800A (fi) 1997-02-26
OA10600A (en) 2000-04-06
NO970861D0 (no) 1997-02-26
ZA957142B (en) 1997-02-25
AP9500754A0 (en) 1995-07-31
SK24897A3 (en) 1998-08-05
BG61840B1 (bg) 1998-07-31
TNSN95092A1 (fr) 1996-02-06
KR970705557A (ko) 1997-10-09
CO4410334A1 (es) 1997-01-09
MX9701538A (es) 1997-05-31
UA45980C2 (uk) 2002-05-15
LV11800A (lv) 1997-06-20
AU691005B2 (en) 1998-05-07
ES2112650T3 (es) 1998-04-01
GB9417310D0 (en) 1994-10-19
HRP950460B1 (en) 2000-02-29
CN1155886A (zh) 1997-07-30
CZ56397A3 (cs) 1998-05-13
YU49287B (sh) 2005-03-15
IS1850B (is) 2003-02-07
DE69501620T2 (de) 1998-07-02
IL115013A (en) 2000-11-21
BG101250A (en) 1997-09-30
JPH09512283A (ja) 1997-12-09
WO1996006842A1 (en) 1996-03-07
PL318319A1 (en) 1997-06-09
AP576A (en) 1997-03-20
DZ1923A1 (fr) 2002-02-17
CN1066727C (zh) 2001-06-06
US6380226B1 (en) 2002-04-30
DE69501620D1 (de) 1998-03-19
TR199501061A2 (tr) 1996-06-21
ATE163182T1 (de) 1998-02-15
CA2198599A1 (en) 1996-03-07
US6110940A (en) 2000-08-29
HRP950460A2 (en) 1997-08-31
HU227822B1 (en) 2012-03-28
DK0776323T3 (da) 1998-03-30
CZ287693B6 (en) 2001-01-17
HUT77310A (hu) 1998-03-30
JP2904588B2 (ja) 1999-06-14
IL115013A0 (en) 1995-12-08
GR3026475T3 (en) 1998-06-30
NO970861L (no) 1997-02-26
YU56995A (sh) 1998-07-10
EP0776323B1 (en) 1998-02-11
PE41596A1 (es) 1996-10-12
RU2159241C2 (ru) 2000-11-20
LV11800B (en) 1997-10-20

Similar Documents

Publication Publication Date Title
SI9520091B (sl) Soli anti-migrenskega derivata indola
DE60218037T2 (de) Neue indolderivate mit affinität zum 5-ht6-rezeptor
Martín et al. Synthesis and conformational study of acridine derivatives related to 1, 4‐dihydropyridines
AU2016240841C1 (en) Crystal of 3,5-disubstituted benzene alkynyl compound
IE58416B1 (en) Polycyclic aromatic compounds
JPS61191683A (ja) 新規な酸性インド−ル化合物
JPH0216315B2 (fi)
PT88669B (pt) Processo para a preparacao de compostos aromaticos e hetero-aromaticos alfa,alfa-di-substituidos utilizados para aumentar a percepcao
JP6768674B2 (ja) 新規ベンズイミダゾール化合物およびその医薬用途
Lahari et al. Design and synthesis of novel isatin derivatives as potent analgesic, anti-inflammatory and antimicrobial agents
CA1108138A (en) Triazine derivatives
Dişli et al. Synthesis and antimicrobial activity of new pyrimidine derivatives incorporating 1H‐Tetrazol‐5‐ylthio moiety
IE58102B1 (en) Active compounds
EP4043457A1 (en) Aromatic heterocyclic compound having tricyclic structure, and preparation method therefor and application thereof
PT70921B (de) Neue indolderivate deren herstellung und deren verwendung als arzneimittel
Sturm et al. (H+-K+)-ATPase inhibiting 2-[(2-pyridylmethyl) sulfinyl] benzimidazoles. 1. Their reaction with thiols under acidic conditions. Disulfide containing 2-pyridiniobenzimidazolides as mimics for the inhibited enzyme
GB2185977A (en) A benzohcinnoline compoun
WO2000078729A1 (en) Crystalline forms of lansoprazole
CA1116629A (en) Troponyl-oxamic acid derivatives and process therefor
EP1440074A1 (en) Olanzapine dihydrate-ii a process for its preparation and use thereof
KR900008814B1 (ko) 살균성 폴리시클릭 화합물의 제조방법
Liang et al. A facile synthesis and herbicidal activities of novel fluorine-containing thiazolo [4, 5-d] pyrimidin-7 (6H)-ones
KR101589910B1 (ko) 결정형 α 탈티레린의 제조방법 및 결정형의 변환방법
SK283188B6 (sk) Spôsob prípravy kryštalickej formy 3/2 hydrátu 7-[(7-(S)- amino-5-azaspiro[2.4]-heptan-5-yl]-8-chlór-6-flór-1-[(1R,2S)-2- flórcyklopropyl]-4-oxo-1,4-dihydrochinolín-3-karboxylovej kyseliny
MX9706339A (es) Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso.

Legal Events

Date Code Title Description
IF Valid on the event date
SP73 Change of data on owner

Owner name: PFIZER IRELAND PHARMACEUTICALS; IE

Effective date: 20050406

SP73 Change of data on owner

Owner name: PFIZER IRELAND PHARMACEUTICALS; IE

Effective date: 20110826